Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway

収録刊行物

  • Leukemia

    Leukemia 32 (4), 960-970, 2017-10-03

    Springer Science and Business Media LLC

被引用文献 (1)*注記

もっと見る

問題の指摘

ページトップへ